Compile Data Set for Download or QSAR
Report error Found 72 Enz. Inhib. hit(s) with all data for entry = 10642
TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448940(N-(5-(4-Ethylpiperazin-1-yl)pyridin-2-yl)-5-fluoro...)
Affinity DataIC50: 0.0700nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448950(N-(5-(1-Ethylpiperidine-4-yl)pyridin-2-yl)-5-fluor...)
Affinity DataIC50: 0.0800nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556330(US11351170, Example 9 | N-(5-((1-ethylpiperidin-4-...)
Affinity DataIC50: 0.100nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556334(US11351170, Example 11 | 3-(4-((6-(5-fluoro-4-(5-f...)
Affinity DataIC50: 0.110nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556335(US11351170, Example 12 | 5-fluoro-4-(5-fluoro-1,1-...)
Affinity DataIC50: 0.110nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448926(1-(2-((5-Fluoro-4-(5-fluoro-1,1-dimethyl-2,3-dihyd...)
Affinity DataIC50: 0.120nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM50455050(CHEMBL4208172 | US10696678, Example 18 | US1135117...)
Affinity DataIC50: 0.140nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556329(US11351170, Example 8 | N-(5-((1-ethylpiperidin-4-...)
Affinity DataIC50: 0.160nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448950(N-(5-(1-Ethylpiperidine-4-yl)pyridin-2-yl)-5-fluor...)
Affinity DataIC50: 0.170nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556328(US11351170, Example 7 | (S)—N-(5-(3-(dimethyl...)
Affinity DataIC50: 0.180nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556327(US11351170, Example 6 | (S)-(3-(dimethylamino)pyrr...)
Affinity DataIC50: 0.200nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556336(US11351170, Example 13 | 5-fluoro-4-(5-fluoro-1,1-...)
Affinity DataIC50: 0.25nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556337(US11351170, Example 14 | 2-(4-(6-(5-fluoro-4-(5-fl...)
Affinity DataIC50: 0.25nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 0.260nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556331(US11351170, Example 10 | 5-fluoro-4-(5-fluoro-1,1-...)
Affinity DataIC50: 0.260nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 0.260nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556326(US11351170, Example 2 | 1-(4-((6-(5-fluoro-4-(5-fl...)
Affinity DataIC50: 0.730nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448940(N-(5-(4-Ethylpiperazin-1-yl)pyridin-2-yl)-5-fluoro...)
Affinity DataIC50: 0.880nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556334(US11351170, Example 11 | 3-(4-((6-(5-fluoro-4-(5-f...)
Affinity DataIC50: 1.02nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556327(US11351170, Example 6 | (S)-(3-(dimethylamino)pyrr...)
Affinity DataIC50: 1.19nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448926(1-(2-((5-Fluoro-4-(5-fluoro-1,1-dimethyl-2,3-dihyd...)
Affinity DataIC50: 1.87nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556335(US11351170, Example 12 | 5-fluoro-4-(5-fluoro-1,1-...)
Affinity DataIC50: 1.89nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448950(N-(5-(1-Ethylpiperidine-4-yl)pyridin-2-yl)-5-fluor...)
Affinity DataIC50: 1.93nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448950(N-(5-(1-Ethylpiperidine-4-yl)pyridin-2-yl)-5-fluor...)
Affinity DataIC50: 2.42nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556331(US11351170, Example 10 | 5-fluoro-4-(5-fluoro-1,1-...)
Affinity DataIC50: 2.46nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM50455050(CHEMBL4208172 | US10696678, Example 18 | US1135117...)
Affinity DataIC50: 2.71nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556337(US11351170, Example 14 | 2-(4-(6-(5-fluoro-4-(5-fl...)
Affinity DataIC50: 2.72nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556330(US11351170, Example 9 | N-(5-((1-ethylpiperidin-4-...)
Affinity DataIC50: 2.90nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 3.41nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 3.41nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556336(US11351170, Example 13 | 5-fluoro-4-(5-fluoro-1,1-...)
Affinity DataIC50: 3.92nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556328(US11351170, Example 7 | (S)—N-(5-(3-(dimethyl...)
Affinity DataIC50: 3.96nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556329(US11351170, Example 8 | N-(5-((1-ethylpiperidin-4-...)
Affinity DataIC50: 4.72nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556326(US11351170, Example 2 | 1-(4-((6-(5-fluoro-4-(5-fl...)
Affinity DataIC50: 8.84nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were respectively dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556338(US11351170, Example 16 | N-(5-((4-ethylpiperazin-1...)
Affinity DataIC50: 9.46nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556330(US11351170, Example 9 | N-(5-((1-ethylpiperidin-4-...)
Affinity DataIC50: 11.3nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448926(1-(2-((5-Fluoro-4-(5-fluoro-1,1-dimethyl-2,3-dihyd...)
Affinity DataIC50: 17.6nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556327(US11351170, Example 6 | (S)-(3-(dimethylamino)pyrr...)
Affinity DataIC50: 19.1nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556327(US11351170, Example 6 | (S)-(3-(dimethylamino)pyrr...)
Affinity DataIC50: 20.4nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556330(US11351170, Example 9 | N-(5-((1-ethylpiperidin-4-...)
Affinity DataIC50: 24.7nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448926(1-(2-((5-Fluoro-4-(5-fluoro-1,1-dimethyl-2,3-dihyd...)
Affinity DataIC50: 36.8nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448950(N-(5-(1-Ethylpiperidine-4-yl)pyridin-2-yl)-5-fluor...)
Affinity DataIC50: 38.3nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556334(US11351170, Example 11 | 3-(4-((6-(5-fluoro-4-(5-f...)
Affinity DataIC50: 44.9nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM448940(N-(5-(4-Ethylpiperazin-1-yl)pyridin-2-yl)-5-fluoro...)
Affinity DataIC50: 46.8nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556328(US11351170, Example 7 | (S)—N-(5-(3-(dimethyl...)
Affinity DataIC50: 50.6nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM50455050(CHEMBL4208172 | US10696678, Example 18 | US1135117...)
Affinity DataIC50: 51.1nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556335(US11351170, Example 12 | 5-fluoro-4-(5-fluoro-1,1-...)
Affinity DataIC50: 55.2nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556331(US11351170, Example 10 | 5-fluoro-4-(5-fluoro-1,1-...)
Affinity DataIC50: 64.1nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556328(US11351170, Example 7 | (S)—N-(5-(3-(dimethyl...)
Affinity DataIC50: 65.5nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Beijing Xuanyi Pharmasciences

US Patent
LigandPNGBDBM556337(US11351170, Example 14 | 2-(4-(6-(5-fluoro-4-(5-fl...)
Affinity DataIC50: 70.3nMAssay Description:Test compounds (compound of the present invention, reference compound Abemaciclib, and comparative example compounds) were dissolved in DMSO at 10 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 72 total ) | Next | Last >>
Jump to: